activity
20202026
most citedMUCE: Bayesian Hierarchical Modeling for the Design and Analysis of Phase 1b Multiple Expansion Cohort Trials

16 citations · 38 across the 11 of their papers we have counts for

collaborators
Showing stat.APShow all

6 papers · 1 filter

stat.AP2025

SIMBA -- A Bayesian Decision Framework for the Identification of Optimal Biomarker Subgroups for Cancer Basket Clinical Trials

Shijie Yuan, Jiaxin Liu, Zhihua Gong +4

We consider basket trials in which a biomarker-targeting drug may be efficacious for patients across different disease indications. Patients are enrolled if their cells exhibit som…

stat.AP2024

The Modified Combo i3+3 Design for Novel-Novel Combination Dose-Finding Trials in Oncology

Jiaxin Liu, Shijie Yuan, Qiqi Deng +1

We consider a modified Ci3+3 (MCi3+3) design for dual-agent dose-finding trials in which both agents are tested on multiple doses. This usually happens when the agents are novel th…

stat.AP2023★ 6 cited

Pharmacometrics-Enabled DOse OPtimization (PEDOOP) for Seamless Phase I-II Trials in Oncology

Shijie Yuan, Zhanbo Huang, Jiaxin Liu +1

We consider a dose-optimization design for first-in-human oncology trial that aims to identify a suitable dose for late-phase drug development. The proposed approach, called the Ph…

stat.AP2023★ 9 cited

The Backfill i3+3 Design for Dose-Finding Trials in Oncology

Jiaxin Liu, Shijie Yuan, B. Nebiyou Bekele +1

We consider a formal statistical design that allows simultaneous enrollment of a main cohort and a backfill cohort of patients in a dose-finding trial. The goal is to accumulate mo…

stat.AP2021★ 5 cited

The Ci3+3 Design for Dual-Agent Combination Dose-Finding Clinical Trials

Shijie Yuan, Tianjian Zhou, Yawen Lin +1

We propose a rule-based statistical design for combination dose-finding trials with two agents. The Ci3+3 design is an extension of the i3+3 design with simple decision rules compa…

stat.AP2021

Lessons Learned from the Bayesian Design and Analysis for the BNT162b2 COVID-19 Vaccine Phase 3 Trial

Yuan Ji, Shijie Yuan

The phase III BNT162b2 mRNA COVID-19 vaccine trial is based on a Bayesian design and analysis, and the main evidence of vaccine efficacy is presented in Bayesian statistics. Confus…